Difference between revisions of "WHIM syndrome"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="float:right; margin-left: 5px;" |- |back to top |}" to "") |
||
| Line 21: | Line 21: | ||
==Plerixafor monotherapy {{#subobject:dc6eae|Regimen=1}}== | ==Plerixafor monotherapy {{#subobject:dc6eae|Regimen=1}}== | ||
| − | + | ||
| − | |||
| − | |||
| − | |||
===Regimen {{#subobject:be34d7|Variant=1}}=== | ===Regimen {{#subobject:be34d7|Variant=1}}=== | ||
{| class="wikitable" style="width: 40%; text-align:center;" | {| class="wikitable" style="width: 40%; text-align:center;" | ||
Revision as of 00:29, 27 July 2022
| Page editor | Section editor | ||
|---|---|---|---|
 |
Ronak H. Mistry, DO Vanderbilt University Nashville, TN  @rmistry91
|
 |
Benjamin Tillman, MD Vanderbilt University Nashville, TN |
WHIM: Warts, Hypogammaglobulinemia, Infections, Myelokathexis
1 regimens on this page
1 variants on this page
|
All lines of therapy
Plerixafor monotherapy
Regimen
| Study | Evidence |
|---|---|
| McDermott et al. 2019 | Pilot, <20 pts |
Growth factor therapy
References
- McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, Liu Q, Trout HH 3rd, Neves JF, Gardner PJ, Bianchi DA, Blair EA, Landon EM, Silva SL, Buck CB, Murphy PM. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019 Jan 10;380(2):163-170. link to original article PubMed